NOTCH1 and adrenal cortex carcinoma: Given the newly emerging role of Notch 1 as an oncogenic driver in ACC (discussed previously in Section 2.3.3), an expansion cohort of the Phase I trial was rolled out to confirm the RP2D effectiveness in 22 ACC patients and to document any observed antitumour activity [292].